Positive results for isatuximab (Sarclisa) in open label Phase 3 IKEMA relapsed mutiple myeloma trial
In this study (n=302), isatuximab was added to standard-of-care treatment carfilzomib and dexamethasone and early results demonstrated a significant reduction in risk of disease progression or death.
Source:
PharmaTimes
SPS commentary:
Isatuximab is a non-TAP antibody consisting of a type II transmembrane glycoprotein CD38-targeting antibody. In March 2020, it was recommended for EU approval by CHMP for use in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.